HAMP and chronic kidney disease: Among trials compared with rhEPO, the HIF-PHIs induced significant reduction in hepcidin was observed only in NDD-CKD patients (MD, −30.86; 95% CI, −52.99 to −8.73; I2 = 56.0%) (Table 3).